GB560631A - Improvements in or relating to water-soluble riboflavin compositions - Google Patents

Improvements in or relating to water-soluble riboflavin compositions

Info

Publication number
GB560631A
GB560631A GB6505/42A GB650542A GB560631A GB 560631 A GB560631 A GB 560631A GB 6505/42 A GB6505/42 A GB 6505/42A GB 650542 A GB650542 A GB 650542A GB 560631 A GB560631 A GB 560631A
Authority
GB
United Kingdom
Prior art keywords
riboflavin
sodium
solution
borate
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6505/42A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Winthrop Chemical Co Inc
Original Assignee
Winthrop Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winthrop Chemical Co Inc filed Critical Winthrop Chemical Co Inc
Publication of GB560631A publication Critical patent/GB560631A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A soluble preparation containing riboflavin which is not excessively alkaline for the purpose of injection comprises at least 0.02 per cent riboflavin and an alkali metal borate in amount corresponding to at least one gram atom of boron per gram-mole of riboflavin. The alkali borate may be sodium tetra borate or sodium metaborate. Of these the former is preferred as the pH of the resulting solution is lower and the solution is more suitable for injection. The corresponding potassium salts may also be used. The ingredients may either be mixed in solution or dry intimate mixtures of sodium or potassium borates may be prepared. There may be added to the solution other vitamins or other therapeutic factors. In examples: (1) a mixture is made of riboflavin sodium hydroxide and sodium borate ( 1/100 mol. of each) in aqueous solution, and the double salt precipitated by a water miscible organic solvent such as acetone, ethyl alcohol, isopropyl alcohol, n-propyl alcohol or dioxane. (2) An aqueous solution is formed of 1/100 mol of riboflavin, potassium hydroxide and potassium borate penta hydrate and precipitated with acetone. (3) An aqueous solution is formed of 1/100 mol. of riboflavin and sodium hydroxide and to this is added 1/50 mol. of sodium metaborate. (4) 1.5 Grams of riboflavin is dissolved in 145 ccs. of 0.1 N-caustic soda and the solution mixed with a solution of 6 grams of boric acid in 200 ccs. of water. The water is removed, e.g. by freezing and the resulting dry powder obtained by evaporation in vacuo in the frozen state sealed into ampules. (5) An aqueous solution containing riboflavin and caustic soda is added to an aqueous solution containing thiamin chloride, vitamin B6, nicotinic acid amide, calcium pantothenate and boric acid. The resulting solution is evaporated to dryness with precautions to prevent decomposition such as evaporation in vacuo in the frozen state. (6) Riboflavin is mixed with sodium borate, if desired in the presence of an inert filler such as milk sugar. The mixture may be dispensed either as a powder or in tablet form. (7) Sodium borate is mixed with riboflavin, thiamin chloride, vitamin B6, calcium pantothenate, sodium nicotinate and also if desired an inert filler such as milk sugar. This mixture also may be dispensed as a powder or in tablet form.
GB6505/42A 1941-04-15 1942-05-13 Improvements in or relating to water-soluble riboflavin compositions Expired GB560631A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US560631XA 1941-04-15 1941-04-15

Publications (1)

Publication Number Publication Date
GB560631A true GB560631A (en) 1944-04-13

Family

ID=22001918

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6505/42A Expired GB560631A (en) 1941-04-15 1942-05-13 Improvements in or relating to water-soluble riboflavin compositions

Country Status (1)

Country Link
GB (1) GB560631A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010790A1 (en) * 2002-07-25 2004-02-05 Horvath Istvan Sweet products with flavin content and methods of producing thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010790A1 (en) * 2002-07-25 2004-02-05 Horvath Istvan Sweet products with flavin content and methods of producing thereof

Similar Documents

Publication Publication Date Title
GB813219A (en) Transparent jelly-type tooth-paste
GB560631A (en) Improvements in or relating to water-soluble riboflavin compositions
GB866840A (en) A process for inhibiting the formation of a precipitate in an aqueous liquid
GB1363834A (en) Sodium aluminium borate and preparation thereof
US2453108A (en) Carbohydrate-boric acid salts of amino aromatic bases
US2332548A (en) Riboflavin preparation and process of making same
ES351689A1 (en) Improvements in or relating to Compositions Containing Choline Chloride
GB722586A (en) Process for fractionating starch
GB1114944A (en) Stilbene-azo and stilbene-azoxy dyes and their preparation
GB822667A (en) Process for the preparation of common salt by the evaporation of solutions
GB1309178A (en) Reducing combustibility
GB1112773A (en) Improvements in or relating to washing bottles and compositions therefor
GB633008A (en) A process for the treatment of complex lithium compounds
GB195317A (en) Improvements in and relating to antiseptics
US2516276A (en) Method of preparing arsenic compounds
GB1046332A (en) Salts of the antibiotic lincomycin
ES243379A1 (en) A procedure for obtaining an optical blanker (Machine-translation by Google Translate, not legally binding)
GB535670A (en) Improved process for the treatment of tinplate and tinplate articles
GB274197A (en) Improvements in the manufacture and production of solid sodium hypochlorite preparations
GB860981A (en) Method and composition for inhibiting corrosion of ferrous metals
GB961838A (en) Pharmaceutical compositions containing phlorophenone derivatives
GB586526A (en) Improvements in or relating to the manufacture of salts of di-isopropyl-salicylic acid
GB931389A (en) Kanamycin salts
GB1172470A (en) A Novel Imidazole Compound and a Process for Producing the same
GB727831A (en) Improvements in or relating to therapeutic preparations containing theophylline